



Office de la propriété  
intellectuelle  
du Canada

Un organisme  
d'Industrie Canada

Canadian  
Intellectual Property  
Office

An Agency of  
Industry Canada

19/1936887

PCT / CA 00 / 00266

28

MARCH


2000

(28.03.00)

CA 00/00266

*Bureau canadien  
des brevets*  
Certification

*Canadian Patent  
Office*  
Certification



(4)

La présente atteste que les documents  
ci-joints, dont la liste figure ci-dessous,  
sont des copies authentiques des docu-  
ments déposés au Bureau des brevets.

This is to certify that the documents  
attached hereto and identified below are  
true copies of the documents on file in  
the Patent Office.

Specification and Drawings, as originally filed, with Application for Patent Serial No:  
2,265,396, on March 12, 1999, by **HSC RESEARCH AND DEVELOPMENT  
LIMITED PARTNERSHIP AND YISSUM RESEARCH DEVELOPMENT  
COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM**, assignee of Chaim  
M. Roifman, Aviv Gazit and Alexander Levitzki, for "Methods and Compositions for  
Treating Leukemia".

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

*S. Gregoire*  
Agent certificateur/Certifying Officer

March 28, 2000

Date

Canada

(CIPO 68)

OPIC



CIPO

## METHODS AND COMPOSITIONS FOR TREATING LEUKEMIA

### Field of the Invention

This invention relates to tyrphostins or benzylidene malononitrile  
 5 compounds which are useful as antiproliferative pharmaceuticals for treating  
 a variety of cell proliferative disorders.

### Background of the Invention


A number of tyrphostins or benzylidene malononitrile derivatives have  
 10 been described which are tyrosine kinase inhibitors and are effective to inhibit  
 cell proliferation, for example in human leukemia (United States Patents Nos.  
 5,217,999 and 5,773,476).

### Summary of the Invention

15 The present invention provides a new group of tyrphostins or  
 benzylidene malononitrile derivatives of improved effectiveness as inhibitors  
 of cell growth.

In accordance with one embodiment, the compounds of the invention  
 have the general formula:

20



25

30

wherein

R<sub>1</sub> is H or C1 to C3 alkyl;

R<sub>2</sub> is aryl or -(CH<sub>2</sub>)<sub>n</sub>- aryl and n is 1 to 4;

$R_3$  is H or  $CH_3$ ; and

$R_4$  is substituted or unsubstituted phenyl, pyridyl, thiophene, furan, indole, pyrrole, thiazole or imidazole.

In accordance with a further embodiment, the compounds have the  
5 general formula I above, wherein

$R_1$  is H, methyl or ethyl;

$R_2$  is phenyl, benzyl,  $-(CH_2)_2$ -phenyl,  $-(CH_2)_3$ -phenyl or 2-thiobenzothiazole;

$R_3$  is H; and

10  $R_4$  is phenyl.

In accordance with a preferred embodiment, the compounds are those shown in Figures 2 to 6.

In accordance with a further embodiment, the invention provides a pharmaceutical composition comprising as active ingredient a compound of  
15 formula I above.

In accordance with a further embodiment, the invention provides a pharmaceutical composition comprising as active ingredient one of the compounds shown in Figures 2 to 6.

In accordance with a further embodiment, the invention provides a  
20 method for treating a cell proliferative disorder in a mammal comprising administering to the mammal an effective amount of a composition which comprises as active ingredient a compound of the formula I above.

In accordance with a further embodiment, the invention provides a method for treating a cell proliferative disorder in a mammal comprising  
25 administering to the mammal an effective amount of a composition which comprises as active ingredient one of the compounds shown in Figures 2 to 6.

Cell proliferative disorders include leukemia, lymphoma, inflammatory disorders, autoimmune diseases and graft rejection.

30 In accordance with a preferred embodiment, the invention provides a method for treating acute lymphoblastic leukemia (ALL) in a mammal comprising administering to the mammal an effective amount of a

composition which comprises as active ingredient a compound of the formula I above.

In accordance with a preferred embodiment, the invention provides a method for treating acute lymphoblastic leukemia (ALL) in a mammal comprising administering to the mammal an effective amount of a composition which comprises as active ingredient one of the compounds shown in Figures 2 to 6.

#### Summary of the Drawings

Figure 1 shows in schematic form a process for synthesising the compounds of the invention.  $R_1$  is C1 to C3 alkyl;  $R_2$  is aryl or  $-(CH_2)_n$ -aryl, where n is 1 to 4;  $R_3$  is H or  $CH_3$ ; and  $R_4$  is substituted or unsubstituted phenyl, pyridyl, thiophene, furan, indole, pyrrole, thiazole or imidazole.

Figures 2 to 6 show some examples of the compounds of the invention.

Figure 7 shows the inhibitory effect (expressed as colony formation/ $1.5 \times 10^5$  cells) of several compounds of the invention on growth of G2 ALL cells.

Figure 8 shows the inhibitory effect of several compounds of the invention on growth of G2 ALL cells.

Figures 9, 10, 11 and 12 show the effect of compounds AG 1977, AG 1978, AG 2009 and AG 2010 respectively on the growth of normal BM cells, as indicated by three different assays.

Figure 13 shows inhibition of G2 ALL cells by various concentrations of the compounds of the invention.

Figure 14 shows a dose response curve of G2 ALL cell inhibition and AG 2009 concentration.

Figure 15 shows inhibition C1 ALL cells by various concentrations of AG 1977 and 1978.

Figure 16 shows inhibition of A1 ALL cells by various concentrations of the compounds of the invention.


Figure 17 shows inhibition of blast cells by several compounds of the invention.

Detailed Description of the Invention

A number of tyrphostins, including the compound  $\alpha$ -cyano-3,4-dihydroxy-cinnamal benzylamide (AG 490), have previously been shown to inhibit the growth of leukemia cells, and to be useful as active ingredients in pharmaceutical compositions for treating leukemia.

The present inventors have found that a new group of substituted benzylidene malononitriles have unexpectedly improved efficacy for treatment of cell proliferative diseases. For example, the inventors have shown that the tyrphostins described herein gave complete suppression of proliferation of human acute lymphoblastic leukemia (ALL) cells and of pre-B ALL blast cells without significantly affecting normal bone marrow cells, as described in the examples.

The compounds of the present invention have the formula:



wherein

R<sub>1</sub> is H or C1 to C3 alkyl;

R<sub>2</sub> is aryl or -(CH<sub>2</sub>)<sub>n</sub>- aryl and n is 1 to 4;

R<sub>3</sub> is H or CH<sub>3</sub>; and

R<sub>4</sub> is substituted or unsubstituted phenyl, pyridyl, thiophene, furan, indole, pyrrole, thiazole or imidazole.

The compounds of the invention are prepared by the process shown schematically in Figure 1. The required aldehydes (a) are available commercially or can be synthesised as previously described (Gazit et al.,

(1993), J. Med. Chem., v. 36, p. 3556). Benzyl cyano acetamide (b) is synthesised as described previously (Gazit et al., (1991), J. Med. Chem., v. 34, p. 1896).

5 A preferred group of compounds are the compounds shown in Figures 2 to 6.

The compounds of the invention may be used to suppress unwanted cell growth in a variety of cell proliferative disorders. Such disorders include leukemia, lymphoma and other forms of cancer, inflammatory disorders and also disorders of the immune system where cell growth suppression is  
10 desired, for example in allergic disorders, autoimmune diseases and graft rejection situations.

The compounds of this invention may be used in the form of the free base, in the form of salts and as hydrates. All forms are within the scope of the invention. Acid addition salts may be formed and provide a more  
15 convenient form for use; in practice, use of the salt form inherently amounts to use of the base form. The acids which can be used to prepare the acid addition salts include preferably those which produce, when combined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the animal organism in pharmaceutical doses of the salts, so  
20 that the beneficial properties inherent in the free base are not vitiated by side effects ascribable to the anions. Although pharmaceutically acceptable salts of the basic compounds are preferred, all acid addition salts are useful as sources of the free base form even if the particular salt per se is desired only as an intermediate product as, for example, when the salt is formed only for  
25 the purposes of purification and identification, or when it is used as an intermediate in preparing a pharmaceutically acceptable salt by ion exchange procedures.

Pharmaceutically acceptable salts within the scope of the invention include those derived from the following acids; mineral acids such as  
30 hydrochloric acid, sulfuric acid, phosphoric acid and sulfamic acid; and organic acids such as acetic acid, citric acid, lactic acid, tartaric acid, malonic

acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, quinic acid, and the like.

Compounds may be examined for their efficacy in inhibiting cell growth in cell proliferation assays such as those described herein.

5 In accordance with the methods of the invention, the described tyrphostins may be administered to a leukemia patient in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art. The compositions of the invention may be administered orally or parenterally, the latter route including intravenous and  
10 subcutaneous administration. Parenteral administration may be by continuous infusion over a selected period of time.

The active compound may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets, or it may  
15 be incorporated directly with the food of the diet. For oral therapeutic administration, the active compound may be incorporated with excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.

The active compound may also be administered parenterally or  
20 intraperitoneally. Solutions of the active compound as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersion can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations  
25 contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersion and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists.

30 The therapeutic compounds of this invention may be administered to a mammal alone or in combination with pharmaceutically acceptable carriers, as noted above, the proportion of which is determined by the solubility and

chemical nature of the compound, chosen route of administration and standard pharmaceutical practice.

Tyrphostins are administered initially in a suitable dosage to provide a blood level of about 10  $\mu$ M. The dosage may be adjusted as required, depending on the clinical response.

An alternate therapeutic approach is to obtain bone marrow or peripheral blood cells containing stem cells from patients with leukemia or lymphoma and to treat these cells ex vivo with a tyrphostin of the invention to purge or kill leukemia or lymphoma cells present with minimal inhibition of normal stem cells. The treated cells are washed to remove excess tyrphostin and returned to the patient.

For such ex vivo treatment of cells over a short period, for example around 5 hours, higher doses of tyrphostin may be used than for long term in vivo therapy; for example, concentrations of 50 $\mu$ M or higher may be used.

#### Examples

##### Example 1 - Synthesis of Compounds

The compounds of the invention were synthesised generally by the process shown schematically in Figure 1.

**Compound AG 1946:  $R_1 = \text{CH}_3$ ,  $R_2 = \text{benzyl}$ ,  $R_3 = \text{H}$**

(a) 207 mg 0.72mM 3-methoxy 4-hydroxy-5-methylene thiobenzyl benzaldehyde, 130 mg 0.75 mM N-benzyl cyano acetamide and 10 mg  $\beta$ -alanine in 25 mL ethanol were refluxed 3 hours. Evaporation and trituration with dichloromethane-hexane gave 305 mg yellow-green solid, 95% yield, mp-135°.

NMR (acetone  $d_6$ )  $\delta$  8.17(1H,s,vinyl), 7.70(1H,d,J=2.1 Hz), 7.57(1H,d,J=2.1 Hz), 7.3(10H,m), 4.60(2H,s), 3.93(3H,s), 3.78(2H,s), 3.74(2H,s).

**Compound AG 1977:  $R_1 = \text{H}$ ,  $R_2 = \text{benzyl}$ ,  $R_3 = \text{H}$**



(b) To 450 mg of product from (a) in 30 mL dichloromethane was added 0.5 mL  $\text{BBr}_3$ . After stirring 1 hour at room temperature, water was added and the reaction extracted with ethyl acetate. Evaporation and trituration with dichloromethane-hexane gave 340 mg, 78% yield, yellow solid, mp-195°.

NMR (acetone  $d_6$ )  $\delta$  8.08(1H,s,vinyl), 7.62(1H,d,J=2.2 Hz), 7.3(11H,m), 4.58(2H,s), 3.78(2H,s), 3.75(2H,s).

MS m/e-430( $\text{M}^+$ ,16%), 175(100%).

**Compound AG 1951:**  $\text{R}_1 = \text{CH}_3\text{CH}_2-$ ,  $\text{R}_2 = \text{Phenyl}$ ,  $\text{R}_3 = \text{H}$

(c) 500 mg 1.74mM 3-ethoxy 4-hydroxy-5-methylene thiophenyl benzaldehyde, 310 mg 1.78 mM N-benzyl cyano acetamide and 25 mg  $\beta$ -alanine in 40 mL ethanol were refluxed 4 hours. Evaporation and trituration with hexane gave 730 mg yellow solid, 95% yield, mp-108°.

NMR (acetone  $d_6$ )  $\delta$  8.10(1H,s,vinyl), 7.70(1H,d,J=2.2 Hz), 7.53(1H,d,J=2.2 Hz), 7.3(10H,m), 4.58(2H,d,J=6.0 Hz), 4.26(2H,s), 4.18(2H,q,J=7.0 Hz), 1.42(3H,t,J=7.0 Hz).

**Compound AG 1978:**  $\text{R}_1 = \text{H}$ ,  $\text{R}_2 = \text{Phenyl}$ ,  $\text{R}_3 = \text{H}$

(d) To 200 mg of product from (c) in 30 mL dichloromethane was added 0.4 mL  $\text{BBr}_3$ . After stirring 1 hour at room temperature water was added and the reaction extracted with ethyl acetate. Evaporation and trituration with dichloromethane-hexane gave 91 mg, 47% yield, yellow solid, mp-175°.

NMR (acetone  $d_6$ )  $\delta$  8.01(1H,s,vinyl), 7.63(1H,d,J=2.2 Hz), 7.3(11H,m), 4.58(2H,s), 4.26(2H,s).

MS m/e- 416( $\text{M}^+$ ,16%), 309(12), 263(32), 196(37), 175(100%).

**Compound AG 2009:**  $\text{R}_3 = \text{H}$ ,  $\text{R}_2 = \text{CH}_2\text{CH}_2\text{Ph}$ .

(e) 400 mg 1.3 mM 3-methoxy 4-hydroxy-5-methylene thiophenetyl benzaldehyde, 240 mg 1.38 mM N-benzyl cyano acetamide and 20 mg  $\beta$ -alanine in 40 mL ethanol were refluxed 4 hours. Evaporation and

trituration with dichloromethane-hexane gave 450 mg yellow solid, 88% yield, mp-102°.

NMR (CDCl<sub>3</sub>) δ 8.25(1H,s,vinyl), 7.62(1H,d,J=2.2 Hz), 7.3(11H,m), 4.61(2H,d,J=6.0 Hz), 3.96(3H,s), 3.81(2H,s), 2.80(4H,m).

5

(f) To 320 mg of product from (e) in 25 mL dichloromethane was added 0.3 mL BBr<sub>3</sub>. After stirring 1 hour at room temperature water was added and the reaction extracted with ethyl acetate. Evaporation and trituration with dichloromethane-hexane gave 110 mg, 35% yield, yellow solid, mp-153°.

10

NMR (acetone d<sub>6</sub>) δ 8.09(1H,s,vinyl), 7.63(1H,d,J=2.2 Hz), 7.3(11H,m), 4.58(2H,s), 3.85(2H,s), 2.80(4H,m).

**Compound AG 2008:** R<sub>1</sub> = CH<sub>3</sub>, R<sub>2</sub> = CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>Ph, R<sub>3</sub> = H

15

(g) 800 mg 2.5 mM 3-methoxy 4-hydroxy-5-methylene thiopropylphenyl benzaldehyde, 430 mg, 2.5 mM N-benzyl cyano acetamide and 20 mg β-alanine in 40 mL ethanol were refluxed 4 hours. Evaporation and trituration with Cc1<sub>4</sub> gave 760 mg yellow solid, 63% yield, mp-78°.

20

NMR (CDCl<sub>3</sub>) δ 8.25(1H,s,vinyl), 7.62(1H,d,J=2.2 Hz), 7.3(11H,m), 4.61(2H,d,J=6.0 Hz), 3.96(3H,s), 3.81(2H,s), 2.69(2H,t,J=6.0 Hz), 2.50(2H,t,J=6.0 Hz), 1.90(2H,quint.,J=6.0 Hz).

**Compound AG 2010:** R<sub>1</sub> = H, R<sub>2</sub> = CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>Ph, R<sub>3</sub> = H

25

(h) To 660 mg of product from (g) in 25 mL dichloromethane was added 0.6 mL BBr<sub>3</sub>. After stirring 1 hour at room temperature water was added and the reaction extracted with ethyl acetate. Evaporation and trituration with dichloromethane-hexane gave 610 mg, 95% yield, yellow solid, mp-138°.

30

NMR (acetone d<sub>6</sub>) δ 8.17(1H,s,vinyl), 7.63(1H,d,J=2.2 Hz), 7.3(11H,m), 4.58(2H,s), 3.80(2H,s), 2.69(2H,t,J=6.0 Hz), 2.52(2H,t,J=6.0 Hz), 1.90(2H,quint.,J=6.0 Hz).

**Compound AG 1976;  $R_1 = OH$ ,  $R_2 = 2$ -thiobenzothiazole,  $R_3 = H$**

(i) 330 mg, 1 mM, 3-methoxy, 4-hydroxy, 5-methylene (2-thio-  
benzothiazole) benzaldehyde, 180 mg, 1.03 mM, N-benzyl cyano  
acetamide and 15 mg  $\beta$ -alanine in 20 ml ethanol were refluxed 4  
hours. Cooling and filtering gave 460 mg, 95% yield, yellow solid.

(j) To 200 mg, 0.4 mM, solid from (i) in 30 ml dichloromethane was  
added 0.4 ml  $BBr_3$ . After stirring 1 hour at room temperature, water  
and 3 ml HCl was added and the reaction extracted with ethyl acetate.  
Evaporation and trituration with dichloromethane-hexane gave 40 mg,  
20% yield, bright yellow solid, mp-225%.

NMR Acetone  $d_6$   $\delta$  8.07(1H,s,vinyl), 7.95(2H,m), 7.6 7.1(9H,m),  
4.60(2H,s), 4.48(2H,d,J=5.9 Hz).

**Example 2 - Inhibition of Colony Formation - Acute Lymphoblastic  
Leukemia (ALL) Cell Lines**

Inhibition of colony formation was studied by methods described  
previously (Kamel-Reid et al., (1992), Leukemia, v. 6, pp. 8-17; Meydan et al.,  
(1996), Nature, v. 379, pp. 645-648).

ALL cell lines A1 (at  $8 \times 10^5$  cells/ml), C1 (at  $4 \times 10^4$  cells/ml) and G2 (at  
 $1.15 \times 10^5$  cells/ml) were plated in 1 ml volumes, in the absence of exogenous  
growth factors, into 35 mm petri dishes (Nunc, Gibco) containing alpha MEM  
(Gibco) plus 10% FCS (Cansera Rexdale, Ont.) in 0.9% (vol/vol)  
methylcellulose (Fluka, Switzerland). Cultures were set up at 37°C with 5%  
 $CO_2$  in a humidified atmosphere and 10  $\mu M$  of a selected tyrphostin was  
added. Colonies consisting of more than 20 cells were counted at 12 days  
(A1), 5 days (C1) and 14 days (G2) using an inverted microscope. The  
results with G2 are shown in Figure 7. Similar results were obtained with A1  
and C1.

**Example 3 - Effect on Bone Marrow Cells**

Compounds showing inhibition of ALL colony formation were examined for their effect on normal bone marrow cells using a modified CFU-GEMM clonogenic assay.

5        The assay was performed according to Fauser and Messner (1978), Blood, v. 52, pp. 1243-8, and Messner and Fauser (1980), Blut, v. 41, pp. 327-333, with some variations. In brief, heparinized bone marrow cells were layered over Percoll (Pharmacia Fine Chemical, Piscataway N.J.) at a density of 1.077 gm/ml and centrifuged at 400 g at 4°C for 10 min. to remove  
10    neutrophils and RBCs. The fractionated bone marrow cells at  $2 \times 10^5$  cells/ml were cultured in IMDM (OCI, Toronto) containing 0.9% (vol/vol) methylcellulose supplemented with 30% FCS (Cansera Rexdale, Ont.) or normal human plasma, a cocktail of cytokines consisting of G-CSF (10 ng/ml, Amgen), IL-3 (40 U/ml, Immunex), MGF (50 ng/ml, Immunex), Erythropoietin  
15    (2u/ml, Epprex) or TPO (10 ng/ml, Amgen) and  $5 \times 10^{-5}$  2-mercaptoethanol. The culture mixture was plated in 1 ml volumes into 35 mm petri dishes and incubated at 37°C with 5% CO<sub>2</sub> in a humidified atmosphere with concentrations of tyrphostin up to 40 µm. The results are shown in Figures 9 to 12.

20        The BFU-E's (erythroid colonies) and the CFU-GEMM (mixed colonies) exhibited inhibition at and above 25µM (Fig. not shown), while the CFU-C's (granulocytes, monocytes and macrophages) showed a dramatic increase of colony proliferation peaking at 25µM and a reduction by 50µM (Fig. not shown). AG 2010 showed significant inhibition at 40µM, while the remaining  
25    compounds showed mild to significant inhibition of erythroid and mixed colonies followed by the myeloid population at 20µM.

**Example 4 - Inhibition of ALL Cells**

Various concentrations of tyrphostins were tested for inhibition of ALL  
30    cells in the clonogenic assay described in Example 2. Compounds AG 1977, 1978, 2007, 2008, 2009 and 2010 were tested against ALL cell lines A1, C1

and G2 in doses ranging from nanomolar to micromolar values. The results are shown in Figures 8, 13, 15 and 16.

AG 2009 demonstrated the most potent clonogenic inhibition, in a dose responsive manner, against G2 cells (Fig. 13). It showed a greater than 50% inhibition at a dose of 16nM and a differential therapeutic index of greater than 2 logs in a survival curve (Fig. 14) of normal BM and G2 colonies.

#### **Example 5 - Inhibition of Blast Cells**

The compounds were further tested in an ALL blast colony assay, against bone marrow samples from two patients with pre -B ALL phenotype based on their FAB classification.

The ALL blast colony assay was performed as described previously (Estrov, Z. et al., (1988), Cancer Res., v. 48, p. 5901) with some modifications. Briefly, heparinized bone marrow cells were layered over Percoll (density 1.077 g/l; Pharmacia Fine Chemicals Piscataway, N.J.) and centrifuged (400g) for 10 minutes at 4°C to remove neutrophils and RBC's. The collected interphase fraction was further enriched for lymphoblasts before plating by using a magnetic cell separator, mini MACS, with separation column (Miltenyi Biotec Inc., 1250 Oakmead Park, Sunnyvale, Ca). With this procedure, ALL blasts were specifically isolated from the marrow mononuclear cell fraction using directly labelled MACS CD19 Microbeads - monoclonal anti-human CD19 (Mouse IgG1, Kappa- Miltenyi Biotec Inc.) and/or indirect magnetic cell labeling using primary biotinylated antibody- (mouse anti-human CD10 monoclonal antibody, Caltag Laboratires, Ca.) and Streptavidin Microbeads (Miltenyi Biotech Inc.). The resulting cell population was composed of 99% lymphoblasts. The positively sorted cells were then cultured at  $2 \times 10^5$  cells/ml in alpha MEM (GIBCO) containing 0.9% (vol/vol) methylcellulose supplemented with 10% FCS (Cansera, Rexdale, Ont.). Irradiated autologous leukemic blasts were used as feeder cells (at  $3 \times 10^5$  cells/ml). Cytokines, normally used, were deleted so that only spontaneous proliferation was evident.

The culture mixture was plated into 35mm petri dishes (Nunc, GIBCO) containing 1ml volumes and incubated at 37°C with 5% CO<sub>2</sub> in a humidified atmosphere. Colonies containing more than 20 cells were scored, using inverted microscope, at 5-7 days.

5 In both cases, significant inhibition of blast colonies was observed (See for example, Figure 17).

#### **Example 6 - Inhibition of Jak2 Kinase Activity**

10 Compounds chosen on the basis of their ability to inhibit the growth (colony formation) of the pre-B leukemia cell line G2 were tested for inhibition of Jak2 kinase.

Jak2 kinase was immunoprecipitated from a 1% Triton-X100 lysate of 10x10<sup>6</sup> G2 cells. An *in vitro* kinase assay was performed on the immunoprecipitated Jak2 in the presence or absence of varying  
15 concentrations of the compounds AG 1977, AG 1978, AG 2009 and AG 2010.

Stock solutions of 100mM tyrphostin were made in 100% DMSO and further dilutions made in 10% DMSO. Control kinase assays carried out in the presence of DMSO concentrations of 5-30% alone were unaffected by its presence.

20 Initial experiments were done with tyrphostin concentrations of 0.1, 1.0 and 10μM. These concentrations had no affect on the kinase activity of Jak2. Using higher concentrations, 5, 25 and 50μM, inhibition could be seen, as shown in Table 1 below. These results were obtained by scanning autoradiographs of the kinase assays.

25

**TABLE 1**

%inhibition of kinase activity

30

Tyrphostin	Concentration		
	5μM	25μM	50μM
AG 1977	23	14	15
AG 1978	10	13	46
35 AG 2009	0	0	8
AG 2010	5	5	39






FIGURE 1





FIGURE 2









FIGURE 3




AG1978



AG 2007

FIGURE 4



AG 2008

FIGURE 5





FIGURE 6




Fig. 7




FIGURE 8




FIGURE 9




FIGURE 10






FIGURE 11




FIGURE 12




Fig. 13




FIGURE 14




FIGURE 15




Fig. 16




Fig. 17



4  
1  
1  
1  
1